B cell activation in rheumatoid arthritis patients under infliximab treatment

Clinical and Experimental Rheumatology

Volumn 21, Issue 6, 2003, Pages 726-732

  De Miguel, S ^a   Jover, J A ^a   Vadillo, C ^a   Judez, E ^a   Loza, E ^a   Fernandez Guiterrez, Benjamin ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Anti TNF alpha; B lymphocytes; CD23; Immunocomplexes

Indexed keywords

CD19 ANTIGEN; CD23 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY CD3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL INTERACTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREGULATION; INFLAMMATORY CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TONSIL;

ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RECEPTORS, IGE; RISK ASSESSMENT; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0347519211     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. AREND WP: The pathophysiology and treatment of rheumatoid arthritis. Arthritis Rheum 1997; 40: 595-7.
2. BLASS S, ENGEL JM, BURMESTER GR: The immunologic homunculus in rheumatoid arthritis. Arthritis Rheum 1999; 42: 2499-506.
3. FERNANDEZ-GUTIERREZ B, HERNANDEZ-GARCIA C, BAÑARES A, JOVER JA: CD23 hyper-expression in rheumatoid arthritis: Evidence for a B cell hyper-responsiveness to cognate and non-cognate T-cell signals. Clin Immunol Immunopathol 1994; 72: 321-7.
4. De MIGUEL S, GALOCHA B, JOVER JA, BAÑARES A, HERNANDEZ-GARCIA C, GARCIA-ASENJO JA, FERNANDEZ-GUTIERREZ B: Mechanisms of CD23 hyperexpression on B cells from patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1222-8.
5. THOMAS R, McILRAITH M, DAVIS LS, LIPSKY PE: Rheumatoid synovium is enriched in CD45RBdim mature memory cells that are potent helpers for B cell differentiation. Arthritis Rheum 1992; 35: 1455-65.
6. MacDONALD KPA, NISHIOKA Y, LIPSKY PE, THOMAS R: Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J Clin Invest 1997; 100: 2404-14.
7. CROW MK, JOVER JA, FRIEDMAN S: Direct T helper-B cell interactions induce an early B cell activation antigen. J Exp Med 1986; 164: 1760-72.
8. De FRANCE T, AUBRY JP, ROUSSET F et al.: Human recombinant interleukin 4 induces Fc receptors (CD23) on normal human B lymphocytes. J Exp Med 1987; 165: 1459-67.
9. CROW MK, KUSHNER B, JOVER JA, FRIEDMAN S, MECHANIC SE, STOHL W: Human peripheral blood T helper cell-induced B cell activation results in B cell surface expression of the CD23 (BLAST-2) antigen. Cell Immunol 1989; 121: 99-112.
10. MOSSALAYI MD, AROCK M, DEBRE P: CD23/Fc epsilon RII: Signaling and clinical implication. Int Rev Immunol 1997; 16: 129-46.
11. AUBRY JP, POCHON S, GRABER P, JANSEN KU, BONNEFOY JY: CD21 is a ligand for CD23 and regulates IgE production. Nature 1992; 358: 505-7.
12. KUMAGAI S, ISHIDA H, IWAI K et al.: Possible different mechanisms of B cell activation in systemic lupus erythematosus and rheumatoid arthritis: Opposite expression of low-affinity receptors for IgE (CD23) on their peripheral B cells. Clin Exp Immunol 1989; 78: 348-53.
13. CHOMARAT P, BRIOLAY J, BANCHEREAU J, MIOSSEC P: Increased production of soluble CD23 in rheumatoid arthritis, and its regulation by interleukin-4. Arthritis Rheum 1993; 36: 234-42.
14. FERNANDEZ-GUTIERREZ B, de MIGUEL S, MORADO C, HERNANDEZ-GARCIA C, BAÑARES A, JOVER JA: Defective early T and T-dependent B cell activation in systemic lupus erythematosus. Lupus 1998; 7: 314-22.
15. TAYLOR PC, WILLIAMS RO, MAINI RN: Immunotherapy for rheumatoid arthritis. Curr Opin Immunol 2001; 13: 611-6.
16. TAYLOR PC: Anti-tumor necrosis factor therapies. Curr Opin Rheumatol 2001; 13: 164-9.
17. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 1681-90.
18. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7.
19. FRANKLIN CM: Clinical experience with soluble TNF p75 receptor in rheumatoid arthritis. Semin Arthritis Rheum 1999; 29: 172-81.
20. KEYSTONE EC: Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27: 427-43
21. MORELAND LW, HECK LW, KOOPMAN WJ: Biologic agents for treating rheumatoid arthritis: concepts and progress. Arthritis Rheum 1997; 40: 397-409.
22. MAINI RN, BREEDVELD FC, KALDEN Jr et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with lowdose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
23. MAINI R, St CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial: ATTRACT Study Group. Lancet 1999; 354: 1932-9.
24. CHARLES PJ, SMEENK RJ, DE JONG J, FELDMANN M, MAINI RN: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor: Findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383-90.
25. PISETSKY DS: Tumor necrosis factor blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 2000; 43: 2381-2.
26. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
27. SANTOS-ARGUMEDO L, ALVAREZ-MAYA I, ROMERO-RAMIREZ H, FLORES-ROMO L: Enforced and prolonged CD40 ligand expression triggers autoantibody production in vivo. Eur J Immunol 2001; 31: 3484-92.
28. MARTINEZ-BARNETCHE J, MADRID-MARINA V, FLAVELL RA, MORENO J: Does CD40 ligation induce B cell negative selection? J Immunol 2002; 168: 1042-9.
29. SALMON JE, PRICOT L: Human receptors for immunoglobulin G. Key elements in the pathogenesis of rheumatic disease. Arthritis Rheum 2001; 44: 739-50.
30. HUNTER S, INDIK ZK, KIM MK, CAULEY MD, PARK JG, SCHREIBER AD: Inhibition of Fc gamma receptor-mediated phagocytosis by a non-phagocytic Fc-gamma receptor. Blood 1998; 91: 1762-8.
31. PHILLIPS NE, PARKER DC: Cross-linking of B lymphocytes Fc gamma receptor and membrane immunoglobulin inhibits anti-immunoglobulin-induced blastogenesis. J Immunol 1984; 132: 627-32.
32. COGGESHALL KM: Negative signaling in health and disease. Immunol Res 1999; 19: 47-64.
33. BOLLAND S, RAVETCH JV: Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity 2000; 13: 277-85.
34. YAMANASHI Y, TAMURA T, KANAMORI T et al.: Role of the rasGAP-associated docking protein p62(dok) in negative regulation of B cell receptor-mediated signaling Genes Dev 2000; 14: 11-6.